GSK Resumes Shipment Of Paxil CR, Plans 30-Day Free Trial Program To Relaunch
This article was originally published in The Pink Sheet Daily
Executive Summary
Paxil CR is back on pharmacy shelves after compliance concerns kept the antidepressant out of production for four months. The company expects to return Avandamet to the market within two weeks. FDA seized all lots of the products in March.
You may also be interested in...
Innovata And SkyePharma Discussing Merger
U.K.-based firms both have expertise in pulmonary delivery systems.
Innovata And SkyePharma Discussing Merger
U.K.-based firms both have expertise in pulmonary delivery systems.
Paxil CR In Recovery, But Still Hobbling GSK’s U.S. Rx Sales Growth
Controlled-release paroxetine recaptures 41% of pre-seizure new prescription share, but the sales interruption still slows growth of GSK’s U.S. pharma business during the second quarter.